Auris announces publication confirming dose-dependent effects of betahistine.
Auris Medical Holding announced the publication of an article confirming dose-dependent effects of betahistine and their relationship to bioavailability in a cat model of surgery-induced acute vertigo. The peer-reviewed article "Betahistine treatment in a cat model of vestibular pathology: pharmacokinetic and pharmacodynamic approaches" was published in Frontiers in Neurology, the second most-cited open-access journal in clinical neurology. The article presents the outcomes of a study with betahistine in a previously established model of acute loss of vestibular function in cats following the unilateral sectioning of the vestibular nerve. The immediate effect of this intervention is the loss of balance and the sensation of vertigo. Thanks to compensatory mechanisms, cats recover their vestibular function over around 40 days. The study demonstrated that daily oral administration of betahistine 2 mg/kg resulted in faster improvement of acute symptoms than with betahistine 0.2 mg/kg. In addition, unlike the lower dose, betahistine 2 mg/kg also accelerated significantly the recovery process; further, it was associated with a significant increase of the histaminergic activity of the tuberomamillary nuclei in the hypothalamus and substantially higher bioavailability in blood plasma.
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 3, 2018|
|Previous Article:||DHT Holdings announces agreement to install scrubbers on twelve of its VLCCs.|
|Next Article:||CACI awarded $48M task order for ETRS services to Naval Surface Warfare Center.|